ArticleFrontiers in medicine2026
Mercury-associated minimal change disease induced by whitening cream: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mercury-associated minimal change disease (M-MCD) is a rare form of secondary minimal change disease (MCD) caused by chronic mercury exposure. Given its rarity and nonspecific clinical presentation, M-MCD is frequently underrecognized in clinical practice. We report the case of a 32-year-old woman who presented with nephrotic syndrome following 4 months of applying a skin-whitening cream. Markedly elevated urinary mercury concentrations were detected, and renal biopsy confirmed MCD with immunoglobulin M (IgM) deposition. The patient received four courses of sodium dimercaptopropane sulfonate chelation therapy combined with glucocorticoids. Complete remission of proteinuria was achieved within 1 month, accompanied by normalization of urinary mercury levels. This case underscores the necessity of obtaining a detailed exposure history in patients with unexplained nephrotic syndrome, particularly among young women using skin-whitening cosmetics. Prompt recognition of mercury exposure and timely chelation therapy are essential for achieving remission; adjunctive glucocorticoids may be considered in selected patients with severe disease or suspected immune- mediated injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.